Immunitybio announces fda approval of anktiva®, first-in-class il-15 receptor agonist for bcg-unresponsive non-muscle invasive bladder cancer

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx), an immunotherapy company, today announced that the u.s. food and drug administration (fda) has approved anktiva (n-803, or nogapendekin alfa inbakicept-pmln) plus bacillus calmette-guÉrin (bcg) for the treatment of patients with bcg-unresponsive non-muscle invasive bladder cancer (nmibc) with carcinoma in situ (cis), with or without papillary tumors. “the fda's approval of anktiva marks our launch of a next-generation immun.
IBRX Ratings Summary
IBRX Quant Ranking